Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies.
about
Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applicationsEarly implementation of QbD in biopharmaceutical development: a practical exampleImproving biophysical properties of a bispecific antibody scaffold to aid developabilityStructure-based prediction of asparagine and aspartate degradation sites in antibody variable regionsAugmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.A comparison of biophysical characterization techniques in predicting monoclonal antibody stability.Statistical characterization of therapeutic protein modifications.Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes.High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy.A novel screening method to assess developability of antibody-like molecules.Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.Aggregation risk prediction for antibodies and its application to biotherapeutic development.Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection.Targeted purification development enabled by computational biophysical modeling.Using extensional flow to reveal diverse aggregation landscapes for three IgG1 molecules.Engineering the expression of an anti-interleukin-13 antibody through rational design and mutagenesis.N-terminal or signal peptide sequence engineering prevents truncation of human monoclonal antibody light chains.9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland.Forced degradation of recombinant monoclonal antibodies: A practical guide.Comparative analysis of monoclonal antibody N-glycosylation using stable isotope labelling and UPLC-fluorescence-MS.Protein deamidation in biopharmaceutical manufacture: understanding, control and impactHigh-throughput screening of antibody variants for chemical stability: identification of deamidation-resistant mutants
P2860
Q26824543-06F41AAB-A4E8-473E-A0FF-D6A43CFB90F5Q26830466-BE341867-70D7-4E49-8B29-7A5DA2B1E8C3Q27679445-F0BD5EEA-1B4A-4F69-94C3-A03A51EC5258Q28539968-E100C199-4DC1-47AD-B3FD-F1EA6AF96542Q35856534-9464E3DD-EBCF-4BBB-AB41-2BCE7603B67DQ37287010-5BC6752F-61BE-4833-A49F-5E85DE9D18ADQ38628116-0E087717-E6F4-4E25-9C7E-D9B8F22BF2B8Q38717942-450402C5-B04E-44EC-92C8-AC464273ECE2Q38718094-03CE6A27-CDD7-4CD9-BA24-642A34460459Q38876656-02832C65-15FB-41AD-BC28-AA5A37BAEB04Q39277950-550D0697-C354-437F-9BB8-0CE7FE4957EEQ39433833-3D308E54-1F41-44D5-8A3F-89B5B57D7A41Q41245711-F6DF180E-5EFB-46C2-905E-1196B03CAA4BQ41596017-65E7698D-3D8F-475B-B452-F07CFB127244Q41720336-895CE194-0F8E-4B07-A4F2-75FEE47229ABQ47190011-5B68A372-1826-4545-9852-F6D8743572A8Q47988148-7DBC3EF7-533F-4671-B4C9-A071123F42CAQ48335716-696A2D41-5EDF-4010-BB8E-77B3B01AFA88Q51238255-7E95A146-F093-46FB-B353-B47828CAF3F2Q53090989-6EB9FA68-3F5F-442A-B82D-B02EF63BDBC4Q53627945-AAEECFC2-0BED-43E7-859B-113F3F5D7191Q57449695-55F62728-9CF5-4862-8BBD-8509193AF8CEQ58748936-3230C918-ED00-4B41-B39B-BA113A17A0E1
P2860
Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Developability studies before ...... lity of monoclonal antibodies.
@en
Developability studies before ...... lity of monoclonal antibodies.
@nl
type
label
Developability studies before ...... lity of monoclonal antibodies.
@en
Developability studies before ...... lity of monoclonal antibodies.
@nl
prefLabel
Developability studies before ...... lity of monoclonal antibodies.
@en
Developability studies before ...... lity of monoclonal antibodies.
@nl
P2093
P2860
P356
P1476
Developability studies before ...... lity of monoclonal antibodies.
@en
P2093
Alexander McCampbell
Alexandre Ambrogelly
Daisy Richardson
David Meininger
Jason Cheung
Jason Rowand
Leslie Mann
Maribel Beaumont
Rico Gunawan
Sabrina Benchaar
P2860
P304
P356
10.4161/MABS.25269
P577
2013-06-07T00:00:00Z